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Abstract
Background: Many of the countries in sub-Saharan Africa are still largely dependent on microscopy as the mainstay
for diagnosis of tuberculosis (TB) including patients with previous history of TB treatment. The available guidance in
management of TB retreatment cases is focused on bacteriologically confirmed TB retreatment cases leaving out those
classified as retreatment ‘others’. Retreatment ‘others’ refer to all TB cases who were previously treated but with
unknown outcome of that previous treatment or who have returned to treatment with bacteriologically negative
pulmonary or extra-pulmonary TB. This study was conducted in 11 regional referral hospitals (RRHs) serving high
burden TB districts in Uganda to determine the profile and treatment success of TB retreatment ‘others’ in
comparison with the classical retreatment cases.
Methods: A retrospective cohort review of routinely collected National TB and Leprosy Program (NTLP) facility data
from 1 January to 31 December 2010. This study uses the term classical retreatment cases to refer to a combined
group of bacteriologically confirmed relapse, return after failure and return after loss to follow-up cases as a distinct
group from retreatment ‘others’. Distribution of categorical characteristics were compared using Chi-squared test for
difference between proportions. The log likelihood ratio test was used to assess the independent contribution of type
of retreatment, human immunodeficiency virus (HIV) status, age group and sex to the models.
Results: Of the 6244 TB cases registered at the study sites, 733 (11.7 %) were retreatment cases. Retreatment ‘others’
constituted 45.5 % of retreatment cases. Co-infection with HIV was higher among retreatment ‘others’ (70.9 %) than
classical retreatment cases (53.5 %). Treatment was successful in 410 (56.2 %) retreatment cases. Retreatment ‘others’
were associated with reduced odds of success (AOR = 0.44, 95 % CI 0.22,0.88) compared to classical cases. Lost to
follow up was the commonest adverse outcome (38 % of adverse outcomes) in all retreatment cases. Type of
retreatment case, HIV status, and age were independently associated with treatment success.
Conclusion: TB retreatment ‘others’ constitute a significant proportion of retreatment cases, with higher HIV prevalence
and worse treatment success. There is need to review the diagnosis and management of retreatment ‘others’.
Background
The World Health Organization (WHO) treatment guide-
lines recommend that all previously-treated TB patients
should be managed according the TB retreatment cat-
egory, while their sputum is cultured and tested for drug
susceptibility (DST) [1]. However, few countries have the
required laboratory capacity to improve access to DST
services to all TB retreatment patients. Therefore, many
countries remain unclear on the best management of TB
retreatment cases. Of particular concern is the category of
TB patients classified as retreatment ‘others’. These refer
to all TB cases, previously treated but with unknown
outcome of that previous treatment or who return for
treatment with bacteriologically negative pulmonary or
extra-pulmonary TB. This study uses the term classical
retreatment cases to refer to all bacteriologically con-
firmed relapse, return after failure and return after lost to
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follow-up (LTFU) cases as a distinct group from retreat-
ment ‘others’.
Uganda has limited capacity to conduct culture and
DST investigations in TB retreatment patients. A study
conducted in three regional referral hospitals (RRHs) in
Uganda showed that only 13 % of 114 registered relapse
smear-positive or treatment after failure cases had their
sputum samples sent to National TB Reference Labora-
tory for culture and DST [2]. Since 2002, Uganda has
notified an increasing number of TB retreatment cases
from 1500 to about 4000 cases per year [3]. Of the
47,650 total TB cases Uganda notified to the WHO in
2013, 4028 (8.5 %) were TB retreatment cases [4]. TB
retreatment ‘others’ constituted a third of the total
retreatment cases notified in 2012 [3].
An important step in understanding how to manage
retreatment ‘others’ is to better understand their out-
comes. Previous studies in other settings have observed
different treatment outcomes, HIV status and manage-
ment approaches between classical TB retreatment cases
and retreatment ‘others’ [5–7]. A study in India found
that retreatment ‘others’ significantly had better treat-
ment outcomes than classical retreatment cases [7].
Another study in Zimbabwe found that retreatment
‘others’ constituted 40 % of recurrent TB with no differ-
ence in treatment outcomes by HIV status [6]. 65 % of
retreatment cases in Malawi were retreatment ‘others’
with over half of them treated with standard TB regimen
for new cases [5]. This study seeks to add this emerging
evidence base on how this group of patients differs by
setting, to answer the following research question: what
is the profile and treatment success of TB retreatment
‘others’ compared to the classical retreatment cases in
Uganda?
Methods
A retrospective hospital-based review of routinely col-
lected TB data on TB retreatment patients started on
TB treatment from 1st January to 31st December 2010.
The data were extracted between May and June 2012.
Study setting
This study was conducted in 11 RRHs of Uganda serving
mostly districts with high TB burden. In 2009, it was ob-
served that districts with RRHs notified an average of
114 retreatment cases each compared to an average of
32 retreatment cases notified by districts without RRHs
(unpublished NTLP reports). The study thus systematic-
ally selected 11 high burden RRHs based on the burden
of TB. The study sites were: Arua, Fort-Portal, Gulu,
Hoima, Jinja, Kabale, Lira, Masaka, Mbarara, Mbale and
Soroti RRHs.
Case definitions and treatment of retreatment TB patients
In Uganda, a TB retreatment case is defined as a person
previously treated with anti-TB drugs for a month or
more and is being treated again, in line with WHO defi-
nitions [1, 8]. The retreatment category is further classi-
fied either as ‘relapse’, ‘treatment after failure’, ‘return
after LTFU’ or ‘others’. Relapses are patients who become
bacteriologically positive after having been treated for TB
and declared cured or treatment completed. Treatment
after failure are patients who, while on first line anti-TB
treatment are bacteriologically positive at 5 months or
later during the course of treatment. Return after LTFU
patients are those who return to treatment and are bac-
teriologically positive after having interrupted treatment
for more than 2 months. Retreatment ‘others’ refer to all
TB cases that do not fit the above definitions such as
patients with history of TB treatment for a month or more
but with no bacteriological confirmation of TB for the
current episode.
In line with WHO definitions, Ugandan NTLP classi-
fies treatment outcomes as; cured, treatment completed,
treatment failure, died, LTFU and transferred-out. Treat-
ment success refers to a combination of cured and treat-
ment completed. In this study, adverse outcome refers
to a combination of LTFU, died, treatment failure and
transferred-out.
The retreatment regimen in Uganda consists of two (2)
months streptomycin (S), rifampicin (R), isoniazid (H),
pyrazinamide (Z), and ethambutol (E). This is followed by
one (1) month RHZE and five (5) months RHE. The
retreatment regimen(2SRHZE/1RHZE/5RHE) is recom-
mended for all bacteriologically positive TB retreatment
cases [1, 8]. Both NTLP and WHO guidelines are silent
on the management of TB retreatment ‘others’ in settings
with limited TB DST capacity. In Uganda, it is at the dis-
cretion of the clinician to decide the TB treatment regi-
men to use in the management of retreatment ‘others’. At
the time of the study, routine culture and DST for retreat-
ment cases had been rolled out to the study sites with
varying levels of implementation [2].
Study variables, source of information and data collection
Records of routinely collected variables within the hospi-
tals’ unit TB registers that were analyzed included:
patient demographic (age and sex); clinical (disease clas-
sification, pre-treatment smear status and HIV status);
treatment-related (type of retreatment and treatment
regimen) characteristics and treatment outcomes. In
Uganda, each TB patient is registered in the unit TB
register by the health facility staff at the start of treat-
ment and individual patient records updated at every
visit during the course of treatment. The district TB and
Leprosy supervisor (DTLS) enters TB patients registered
on treatment from all TB diagnostic and treatment
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health facilities within that particular district into the
district TB register. Information on patients that trans-
ferred to other facilities within the same district is cap-
tured by the DTLS and conveyed back to the registering
facility. More information on patients transfers between
districts in the same zone is exchanged during quarterly
zonal performance reviews attended by DTLSs before
compiling quarterly district TB and Leprosy reports on
notification and treatment outcomes. At the time of the
study, the reporting unit at the NTLP central unit was
the district. Using an anonymous standardized data col-
lection tool, study variables were extracted from the hos-
pital’ TB unit registers by one trained research assistant
and all entries were verified by the first author. The
respective district TB registers were used to ascertain
definitive patient treatment outcomes that were missing
in the unit registers.
Data entry and analysis
Data was entered into EpiData version 3.1 (The EpiData
Association, Odense, Denmark)and analyzed in STATA
version 11.2 (Stata Corp, College Station, TX, USA).
HIV status was categorized into positive, negative and
unknown. Age was categorized using cut offs that made
meaningful differences between the categories. Descrip-
tive analysis of patient characteristics was computed.
Distribution of patient characteristics by type of retreat-
ment cases (classical vs. retreatment ‘others’) was com-
puted. The differences in distribution of categorical
characteristics were compared using Chi-square test for
difference between proportions at a significance level of
P-value equal to 0.05.
Treatment outcome was analyzed as a binary variable
of success versus all other outcomes. Odds ratio was the
measure of association. Logistic regression was used to
identify patient characteristics that were independently
associated with treatment success. Characteristics that
had P-value equal or less than 0.05 at bivariate level
were assessed further in a multivariate model. In the
multivariate analysis, characteristics that were not sig-
nificant at p-value equal or less than 0.05 were dropped.
The multivariable model was determined using forward
regression with a two-sided P-value equal or less than
0.05. Sex was included as a priori in the final model. The
log likelihood ratio test was used to assess the independ-
ent contribution of explanatory variables to the models.
Ethical approval
As this study was a review of routinely collected NTLP
data at RRHs, approval was obtained from Ministry of
Health and Joint Clinical Research Centre Institutional
Review Board as the local ethical body. The protocol
was also approved by London School of Hygiene Trop-
ical Medicine ethics review committee.
Results
Of the 6244 TB cases registered at the 11 RRHs, 733
(11.7 %) were retreatment cases (Fig. 1). Three retreat-
ment cases were excluded from subsequent analyzes due
to contradictory records. Table 1 shows that majority of
Fig. 1 Proportion of TB retreatment cases and outcomes at eleven regional referral hospitals, Uganda
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retreatment cases were males (71.6 %) and in age group
15–44 years (70 %). Overall, 690 (94.5 %) retreatment
cases had a documented HIV test result.
Retreatment ‘others’ constituted 45.5 % of retreatment
cases. Like the classical retreatment cases, retreatment
‘others’ were mostly males (65 %), and in the age group
15–44 years (65 %). Significantly, lesser (62 %) of retreat-
ment ‘others’ were treated with the standard retreatment
regimen (2SRHZE/1RHZE/5RHE) compared to 95 % of
classical retreatment cases. About a third of the retreat-
ment ‘others’ were treated with the standard regimen for
new TB patients.
Table 2 shows that HIV prevalence was higher among
retreatment ‘others’ (70.9 %) than classical retreatment
cases (53.5 %). HIV co-infection was 61.5 % among 690
retreatment patients that had a documented HIV test re-
sult. Females had a higher HIV prevalence (70.7 %) than
males (57.8 %). Of the 424 patients with an HIV-positive
test result, 385 (91 %) and 221 (52 %) were provided
with Cotrimoxazole preventive therapy (CPT) and anti-
retroviral therapy (ART) respectively.
Table 3 shows that treatment was successful in 410
(56.2 %) of the 730 retreatment cases. Adverse outcomes
were; 16.4 % LTFU, 9.9 % died, 2.6 % failed on treatment
Table 1 Frequency of retreatment TB patients’ characteristics and their distribution by type of retreatment cases registered at the
eleven RRHs, 2010 (n = 730 cases)
Characteristic All retreatment cases Type of retreatment cases P-value*
Classical TB retreatment cases; TB retreatment ‘others’;
n (%) n = 398 (%) n = 332 (%)
Sex
Male 523 (71.6) 308 (77.4) 215 (64.8) <0.001
Female 207 (28.4) 90 (22.6) 117 (35.2)
Age (years)a
<15 39 (5.4) 3 (0.8) 36 (10.8) <0.001
15-44 509 (69.8) 293 (73.8) 216 (65.1)
>44 181 (24.8) 101 (25.4) 80 (24.1)
Anatomical site
Pulmonary 689 (94.4) 398 (100.0) 291 (87.7) <0.001
Extrapulmonary 41 (5.6) 0 (0.0) 41 (12.3)
Disease classification
Sputum smear-positive 400 (54.8) 398 (100.0) 2 (0.6) <0.001
Sputum smear-negative 267 (36.6) 0 (0.0) 267 (80.4)
No smear done 22 (3.0) 0 (0.0) 22 (6.6)
Extrapulmonary 41 (5.6) 0 (0.0) 41 (12.4)
HIV status
Negative 266 (36.4) 174 (43.7) 92 (27.7) <0.001
Positive 424 (58.1) 200 (50.3) 224 (67.5)
Unknown 40 (5.5) 24 (6.0) 16 (4.8)
Retreatment sub-category
Sputum smear-positive relapse 196 (26.9) 196 (49.3) 0 (0.0) <0.001
Sputum smear-positive failure 44 (6.0) 44 (11.1) 0 (0.0)
Sputum smear-positive return after LTFU 158 (21.6) 158 (39.7) 0 (0.0)
Retreatment ‘others’ 332 (45.5) 0 (0.0) 332 (100.0)
Treatment regimen
Retreatment: 2SRHZE/1RHZE/5RHE 582 (79.7) 378 (95.0) 204 (61.5) <0.001
New: 2RHZE/6EH or 2RHZ/4RH 116 (15.9) 19 (4.8) 97 (29.2)
Other regimenb 32 (4.4) 1 (0.2) 31 (9.3)
*P-values are from Pearson’s chi-squared test or Fisher’s exact test for the difference in the distribution of the categorical characteristics across the types of
retreatment cases
a1 patient had missing data
bOther regimen included: 3RHZE/5RHE = 13; 2SRHZ/4-12RH = 14; 2SRHZE/6EH = 2; 3SRH/6RH = 1; unknown = 2
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while 5.1 % transferred-out and 9.9 % were not-
evaluated. Table 4 shows that retreatment ‘others’ were
associated with reduced odds of treatment success [odds
ratio (OR) =0.65, 95 % CI 0.48, 0.87] compared to the
classical retreatment cases. Anatomical site and treat-
ment regimen were not associated with treatment suc-
cess. Using multivariable analysis, odds of treatment
success remained lower among retreatment ‘others’
compared to the classical retreatment cases after adjust-
ing for age group, HIV status and sex (Adjusted OR
(AOR)) = 0.60, 95% CI 0.44, 0.82). Unknown HIV status
was significantly associated with lower odds of treatment
success compared to known HIV status (AOR = 0.44,
95% CI 0.22, 0.88). Together with type of retreatment
case, age group (less than 15 years) became significantly
associated with treatment success (AOR = 2.32, 95% CI
1.12, 4.81).
Discussion
Retreatment ‘others’ constitute almost half of the retreat-
ment cases in the RRHs of Uganda. Compared to the
classical retreatment cases, more cases of retreatment
‘others’ were HIV positive. And more than a third of
retreatment ‘others’ were not managed with the standard
retreatment regimen. Fewer (half ) retreatment ‘others’
succeeded on treatment (50.3 %) compared to six in ten
of the classical retreatment cases (61.1 %). Lost to follow
Table 2 Prevalence of HIV by patient characteristics, retreatment type among retreatment TB patients with known HIV test results at
eleven RRHs, Uganda (n = 690)
Characteristic Total Classical retreatment cases ‘Others’ retreatment cases P-value*
HIV Positive HIV Positive HIV Positive
n (%) n (%) n (%)
Overall 690 424b (61.4) 374 200 (53.5) 316 224 (70.9) <0.001**
Sex
Male 492 284 (57.8) 289 145 (50.2) 203 139 (68.5) 0.022
Female 198 140 (70.7) 85 55 (64.7) 113 85 (75.2)
Age group, yearsa
<15 35 24 (68.6) 3 2 (66.7) 32 22 (68.8) <0.001
15-44 488 316 (64.8) 277 157 (56.7) 211 159 (75.4)
>44 166 83 (50.0) 94 40 (42.6) 73 43 (58.9)
Anatomical site
Pulmonary 650 391 (60.2) 374 200 (53.5) 276 191 (69.2) <0.001
Extrapulmonary 40 33 (82.5) 0 0 (0.0) 40 33 (82.5)
Treatment regimen
Retreatment: 2SRHZE/1RHZE/5RHE 553 329 (59.5) 357 192 (53.8) 196 137 (69.9) <0.001
New:2RHZE/6EH or 2RHZ/4RH 106 73 (68.9) 16 8 (50.0) 90 65 (72.2)
Other regimen 31 22 (71.0) 1 0 (0.0) 30 22 (73.3)
*P-values are from either Pearson’s chi-squared test of Fischer’s exact tests for the difference between given characteristics and the type of retreatment among
only HIV positive patients
**P-value from Z-test for two proportions
a1 patient had missing data on this variable
bCotrimoxazole preventive therapy and antiretroviral treatment were documented among 385 (91 %) and 221 (52 %) of all HIV positive TB retreatment
patients respectively
Table 3 Outcomes of retreatment cases by WHO retreatment category
Type of retreatment Treatment outcome Adverse outcomes
Successful Adverse Failure Died LTFU Transfer-out Not -evaluated
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Smear-positive relapse: n = 196 134 (68.4) 62 (31.6) 9 (4.6) 9 (4.6) 23 (11.7) 7 (3.6) 14 (7.0)
Smear-positive return after failure: n = 44 30 (68.2) 14 (31.8) 4 (9.1) 3 (6.9) 5 (11.4) 0 (0.0) 2 (4.5)
Smear-positive return after LTFU: n = 158 79 (50) 79 (50.0) 3 (1.9) 19 (12) 26 (16.4) 12 (7.6) 19 (12.0)
Retreatment ‘others’: n = 332 167 (50.3) 165 (49.7) 3 (0.9) 41 (12.3) 66 (19.9) 18 (5.4) 37 (11.0)
Total; n = 730 410 (56.2) 320 (43.8) 19 (2.6) 72 (9.9) 120 (16.4) 37 (5) 72 (9.9)
P < 0.001 for the difference between the type of retreatment and treatment outcome using Pearson’s chi-squared test
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up was the commonest adverse outcome for both retreat-
ment groups.
Nearly half of the retreatment cases in this study
were retreatment ‘others’ compared to one in three
cases notified nationally [3]. Probably, RRHs receive
mostly very sick patients whose sputum is likely to test
negative on Ziehl Neelsen (ZN) smear test due to their
inability to mount an immune response and/ or pro-
duce sufficient sputum for microscopy. In addition, the
TB diagnosis in RRHs is likely to be made by relatively
highly qualified clinicians with capacity and/or bias to
rely on their clinical acumen to diagnose TB even in
the absence of a positive AFB sputum result. The pres-
ence of high TB-HIV co-infection rates in our study
may account for the observed high proportion of
retreatment ‘others’ [9]. The proportion of retreatment
‘others’ in this study is comparable to those from
Zimbabwe and India [6, 7], but less than the propor-
tion observed from a study conducted in a large regis-
tration centre of Malawi [5].
Overall, treatment success was low at 50 % in retreat-
ment ‘others’ and 61 % in classical retreatment cases,
compared to 71 % treatment success notified to WHO
[3]. This study considered patients in referral hospitals
who may be different from other TB patients from lower
levels of care on a number of factors. Due to the referral
cascade, patients with atypical forms of TB or drug-
resistant TB are likely to be managed at RRHs and hence
likely to exhibit poor treatment outcomes. However, the
observed factors like the weakness in recording and
reporting system, inability to track these patients (15 %
of participants didn’t have definitive outcomes) and the
low uptake of ART (52 %) among HIV co-infected
patients may also explain the low treatment success. The
52 % ART uptake observed in the study population was
higher than the national average of 24 % [10]. The differ-
ence between treatment success in this study and that
reported to WHO may be because we evaluated all
retreatment cases registered and not only classical retreat-
ment cases that are routinely evaluated. Nonetheless, the
Table 4 Patient characteristics associated with binary treatment success among TB retreatment cases registered in eleven RRHs of
Uganda (n = 730)
Characteristics Total Treatment Success n (%) Unadjusted OR (95 % CI) P-value* Adjustedb OR (95 % CI) P-value*
Overall 730 410 (56.2)
Type of retreatment case
Classical retreatment cases 398 243 (61.1) 1.00 1.00
Retreatment ‘others’ 332 167 (50.3) 0.65 (0.48, 0.87) 0.004** 0.60 (0.44, 0.82) 0.001**
HIV status
Positive 424 236 (55.7) 1.00 1.00
Negative 266 159 (59.8) 1.18 (0.87, 1.62) 0.288 1.13 (0.82, 1.56) 0.452
Unknown 40 15 (37.5) 0.48 (0.24, 0.93) 0.030** 0.44 (0.22, 0.88) 0.020**
Age groupa
15-44 509 292 (57.4) 1.00 1.00
<15 39 27 (69.2) 1.67 (0.83, 3.37) 0.143 2.32 (1.12, 4.81) 0.024**
≥45 181 90 (49.7) 0.73 (0.52, 1.03) 0.073 0.75 (0.53, 1.06) 0.102
Sex
Male 523 296 (56.6) 1.00 1.00
Female 207 114 (55.1) 0.94 (0.68, 1.30) 0.708 0.97 (0.69, 1.35) 0.844
Anatomical site
Pulmonary 689 388 (56.3) 1.00
Extrapulmonary 41 22 (53.7) 0.90 (0.48, 1.69) 0.739
Treatment regimen
Retreatment: 2SRHZE/1RHZE/5RHE 582 322 (55.3) 1.00
New: 2RHZE/6EH or 2RHZ/4RH 116 66 (56.9) 1.07 (0.71, 1.59) 0.756
Other regimen 32 22 (68.8) 1.78 (0.83, 3.82) 0.137
*Wald P-value
**Significant at P = 0.05
a1 patient had missing data
bAdjusted for HIV status, age, and sex
Nabukenya-Mudiope et al. BMC Public Health  (2015) 15:840 Page 6 of 8
results support previous findings from a smaller study
conducted in three RRHs in Uganda [2].
The outcomes for retreatment ‘others’ in this study were
worse than those of retreatment ‘others’ reported in India
as compared to the classical retreatment cases [7]. This
difference across settings may be influenced by factors
such as difference in treatment regimens’ [5], drug resist-
ance [11], co-morbidity [12], delay in diagnosis or even
misdiagnosis [5, 13], adherence levels or having another
pulmonary or extra-pulmonary disease for which they are
not adequately treated.
Similar to the results reported in previous studies [5, 6],
this study found that a higher proportions of retreatment
‘others’ were co-infected with HIV compared to the clas-
sical retreatment cases. Just like in other studies, we found
that patients’ knowledge of their HIV status is beneficial
[9, 14, 15]. 90 % of study participants that were found to
be HIV-positive were started on CPT and half of them
started on ART as well. The high uptake of HIV testing
coupled with good initiation of CPT in this study could
have resulted in observing no difference in treatment suc-
cess between HIV-positive and negative patients. Age
group and unknown HIV status were only significant in-
dependent predictors, but did not modify the effect of type
of TB retreatment case on treatment outcome.
The findings of this study should be viewed with the
following limitations. Firstly, this was a retrospective
study utilizing hospital TB registers which could be
prone to inaccuracies resulting from poor recording and
completeness in the patient data and compromise the
validity of the finding. However, this study found that
94.5 % of smear-positive retreatment cases had smear re-
sult correctly recorded. In addition, completeness of
treatment outcomes was improved by use of the district
TB registers whereby 28 % (176/621) of definitive out-
comes among study participants were obtained.
We could not establish treatment outcomes in 15 % of
the study participants even after reviewing district TB
registers. There were no differences in patient character-
istics between those who had complete information on
the outcomes and those who had missing outcomes.
However, the high proportion of missing treatment out-
come could have introduced bias in determining treat-
ment success or underreported deaths or LTFU among
the study participants.
This study highlights the importance of ensuring ap-
propriate management for retreatment ‘others’ given the
relatively poor outcomes. A first key step is to ensure
that this high number of retreatment ‘others’ is not a re-
sult of misdiagnosing drug-resistant TB or a false posi-
tive diagnosis of TB. More accurate TB diagnostic tools
like the GeneXpert MTB/RIF that are currently available
in all the study sites may have a role in providing access
to a confirmation of TB in this special group.
Secondly, the continued notification of high proportions
of retreatment ‘others’ to national authorities and Global
TB Program calls for clear guidance on the management
of retreatment ‘others’ including further definition of
treatment regimen(s) in high HIV prevalence settings and
limited TB diagnostic capacity. A future prospective study
involving culture and drug-susceptibility testing could be
conducted in programmatic settings to further understand
the appropriate treatment regimens in such patients.
Thirdly, the observed high LTFU in the retreatment
patients especially the retreatment ‘others’ calls for fo-
cused and innovative interventions to ensure treatment
adherence in this group of patients. Social incentives
and community outreach may have a role to play in re-
ducing the loss to follow-up of these groups.
Fourthly, high HIV prevalence among retreatment
cases especially the TB retreatment ‘others’ calls for bet-
ter strategies of improving provision of the full range of
TB/HIV collaborative services to reduce the burden of
HIV in this group of patients.
Finally, further research is recommended at different
levels of the TB treatment program to further clarify the
importance of patient, health worker and system related
factors on treatment success among retreatment cases to
complement the findings of this study; and design the most
appropriate response to ensure favorable outcomes from
this underserved and evaluated group of TB patients.
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